IMIGRAN 50/MG TAB 2/TAB

Indications

Approved Uses

Acute treatment of migraine attacks with or without aura in adults.

Off-Label Uses

Off-label examples: acute cluster headache (typically subcutaneous or intranasal formulations), and short-term perimenstrual migraine prophylaxis (intermittent dosing).

Dosage & Administration

Dosing by Condition

Migraine (oral tablet): 50 mg as a single dose (some patients may use 25-100 mg depending on response/tolerability). If the migraine improves but returns, a second dose may be taken ≥2 hours after the first; maximum 200 mg in 24 hours. If there is no response to the first dose, do not repeat for the same attack.

Initial Dose

50mg to 100mg orally at the onset of migraine symptoms.

Maintenance Dose

A second dose of 25-100mg may be taken at least 2 hours after the first dose if the migraine recurs.

Maximum Dose

200 mg per 24 hours (oral tablets).

Children's Dosage

Not approved for children, but used off-label for migraines in children and adolescents.

Dose Adjustment Notes

Hepatic impairment: in mild to moderate hepatic impairment, the maximum single oral dose should not exceed 50 mg; avoid oral sumatriptan in severe hepatic impairment. If 50 mg is ineffective, 100 mg may be tried in a subsequent attack (not as an extra dose for the same non-responding attack).

Side Effects

Common Side Effects

Tingling/numbness (paresthesia), flushing and sensations of warmth/cold, dizziness, drowsiness/fatigue/weakness, nausea/vomiting, and chest/throat/neck/jaw tightness or pressure sensations.

Side Effect Frequency

Common (1-10%): sensations of tingling/heat/flushing, pressure/heaviness/tightness (including chest/throat), dizziness, drowsiness/somnolence, nausea/vomiting, fatigue/weakness; Very rare (<0.01%): minor disturbances in liver function tests.

Safety & Warnings

Contraindications

Ischemic heart disease (including prior MI), coronary vasospasm/Prinzmetal’s angina, history of stroke or TIA, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, severe hepatic impairment, hemiplegic or basilar migraine, hypersensitivity to sumatriptan; concomitant use (or within 24 h) of ergotamine/ergot derivatives or another triptan/5‑HT1 agonist; use within 2 weeks of MAO‑A inhibitors.

Warnings & Precautions

For acute treatment only (not prophylaxis) and after migraine diagnosis; assess cardiovascular risk and consider evaluation before first use in patients with risk factors; risk of vasospasm and serious cardiac/cerebrovascular events; avoid in hemiplegic/basilar migraine; medication-overuse headache can occur (avoid frequent use, e.g., >10 days/month); caution with controlled hypertension, hepatic impairment, and history of seizures; consider serotonin syndrome risk with serotonergic drugs.

Age Restriction

Not approved/recommended for patients <18 years (safety and efficacy not established).

Driving Warning

May Cause Drowsiness

Special Populations

Children

Not approved for children, but used off-label for migraines in children and adolescents.

Liver Impairment

Mild to moderate impairment: Maximum single oral dose of 50mg. Severe impairment: Contraindicated.

Storage & Patient Advice

Missed Dose

Not applicable-used as needed for acute migraine attacks, not on a fixed schedule.

Patient Counseling

Take 50 mg at the start of migraine pain (not for prevention). If you improve then the headache returns, you may repeat 50 mg after at least 2 hours; do not exceed 200 mg in 24 hours. If there is no relief from the first dose, do not take a second dose for the same attack. Seek urgent care for chest pain/tightness, shortness of breath, weakness, or symptoms of stroke; avoid using with other triptans within 24 hours or with ergot medicines within 24 hours, and tell your clinician about antidepressants/other serotonergic drugs. Overuse (e.g., frequent use on many days per month) can worsen headaches.

Pharmacology

Mechanism of Action

Selective 5-HT1B/5-HT1D receptor agonist that constricts dilated cranial vessels and inhibits trigeminal neurotransmission/neuropeptide release, aborting migraine attacks.

Onset of Action

Oral tablet: typically 30-60 minutes (with meaningful assessment at ~2 hours).

Duration of Effect

Clinical benefit is typically assessed within 2 hours; recurrence can occur within 24 hours and a second dose may be used for recurrence (not a guaranteed 24-hour duration of relief).

Product Information

Available Dosage Forms

Oral tablet, Subcutaneous injection, Nasal spray, Nasal powder, Rectal suppository.

Composition per Dose

Each tablet: 50mg sumatriptan as sumatriptan succinate.

Generic Availability

Yes

Pain Type

Migraine

Nsaid

No

Opioid

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.